List of investigational antipsychotics
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in December 2017. It is likely to become outdated with time.
Receptor modulators
[edit]Monoamine receptor modulators
[edit]- Brilaroxazine (RP5063; oxaripiprazole) – atypical antipsychotic (D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist)[1]
- FKF-02SC (TGOF-02N) – atypical antipsychotic (D2 and 5-HT2A receptor antagonist, other actions)[2]
- Masupirdine (SUVN-502) – 5-HT6 receptor antagonist[3]
- N-Methylamisulpride (LB-102) – D2,3, 5-HT7, receptor antagonist (methylated version of amisulpride)[4]
- Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist[5]
- Ulotaront (SEP-856, SEP-363856) – 5-HT1A receptor and TAAR1 agonist[6]
- Usmarapride (SUVN-D4010) – 5-HT4 receptor partial agonist[7]
Glutamate receptor modulators
[edit]- Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR2 and mGluR3 agonist[8]
- Iclepertin – glycine transporter-1 inhibitor[9]
Acetylcholine receptor modulators
[edit]- Emraclidine (CVL-231) – M4 muscarinic acetylcholine receptor positive allosteric modulator.[10]
- ML-007 – M1 and M4 muscarinic acetylcholine receptor agonist.[11]
- NBI-1117568 (HTL 0016878) – M4 muscarinic acetylcholine receptor agonist.[12]
- NS-136 – M4 muscarinic acetylcholine receptor positive allosteric modulator[13]
Cannabinoid receptor modulators
[edit]- Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions[14][15]
Other/mixed receptor modulators
[edit]- CVN766 – Orexin receptor type 1 antagonist[16]
- Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions[17][18]
- Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT2A and σ2 receptor antagonist[19]
- TAK-041 (NBI 1065846) – GPR139 receptor agonist[20]
Enzyme inhibitors
[edit]- Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor.[21] (DAAO is a pathway to NMDAR.[22])
- MK-8189 – phosphodiesterase 10A inhibitor.[23]
- Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor[24]
- Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor[25]
Ion channel modulators
[edit]Others
[edit]- TS-134 (TS-1341) – undefined mechanism of action[27]
- Kratom – Has shown antipsychotic-like effects on par with haloperidol in animal testing[28][29]
See also
[edit]References
[edit]- ^ "Brilaroxazine - Reviva Biopharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "FKF 02SC - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "Masupirdine - Suven Life Sciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "N-methyl amisulpride - LB pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved February 21, 2023.
- ^ "Ralmitaront - AdisInsight". adisinsight.springer.com. Springer. Retrieved July 10, 2021.
- ^ "SEP 363856 - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "SUVN D4010 - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ O'Brien, Erin (June 18, 2024). "New Baseline Data on Iclepertin for Schizophrenia". Vol 41, Issue 6.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Emraclidine - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved February 15, 2023.
- ^ "ML 007 - AdisInsight". adisinsight.springer.com. Retrieved February 15, 2023.
- ^ "HTL 0016878 - AdisInsight". adisinsight.springer.com. Retrieved February 21, 2023.
- ^ "NS 136". AdisInsight. May 15, 2024. Retrieved October 20, 2024.
- ^ "Cannabidiol - GW Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "Cannabidiol - Echo Pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved February 14, 2020.
- ^ "CVN 766 - AdisInsight". adisinsight.springer.com. Retrieved February 19, 2023.
- ^ "Deudextromethorphan - Avanir Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ Nguyen, Linda; Thomas, Kelan L.; Lucke-Wold, Brandon P.; Cavendish, John Z.; Crowe, Molly S.; Matsumoto, Rae R. (March 2016). "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders". Pharmacology & Therapeutics. 159: 1–22. doi:10.1016/j.pharmthera.2016.01.016. ISSN 1879-016X. PMID 26826604.
- ^ "Roluperidone - Minerva Neurosciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "TAK 041 - AdisInsight". adisinsight.springer.com. Retrieved February 21, 2023.
- ^ "Luvadaxistat - Takeda - AdisInsight". adisinsight.springer.com. Retrieved February 21, 2023.
- ^ Vita, Antonio; Nibbio, Gabriele; Barlati, Stefano (January 2024). "Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives". Schizophrenia Bulletin Open. 5 (1): sgae013. doi:10.1093/schizbullopen/sgae013. ISSN 2632-7899. PMID 39144119.
- ^ "MK 8189 - AdisInsight". adisinsight.springer.com. Retrieved February 21, 2023.
- ^ "BI 409306 - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "Sodium benzoate - SyneuRx - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "Evenamide - Newron Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ "TS 134 - AdisInsight". adisinsight.springer.com. Springer. Retrieved February 14, 2020.
- ^ Vijeepallam, K.; Pandy, V.; Kunasegaran, T.; Murugan, D. D.; Naidu, M. (2016). "Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice". Frontiers in Pharmacology. 7: 464. doi:10.3389/fphar.2016.00464. PMC 5138496. PMID 27999544.
- ^ Johnson, L. E.; Balyan, L.; Magdalany, A.; Saeed, F.; Salinas, R.; Wallace, S.; Veltri, C. A.; Swogger, M. T.; Walsh, Z.; Grundmann, O. (2020). "The Potential for Kratom as an Antidepressant and Antipsychotic". The Yale Journal of Biology and Medicine. 93 (2): 283–289. PMC 7309668. PMID 32607089.